Why 8% to 10% ? This is my approximation of the growth of pharma investment in to CNS related indications, could it be higher 15% or 20% yes it certainly could but 10% feels about right.
I think with the promising data from Lecanemab Clarity AD trial update and of course the Lilly Phase II Donanemab results, some of the pressure has been released from Aducanumab being the only game in town. This was not the case when you had the various trial cancellations a couple of years back.
CGS Price at posting:
92.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)